Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1992)
  2. Solid Tumor Oncology Division (1623)
  3. GSK Faculty (765)
  4. Survivorship Research (637)
  5. Population Sciences Research Program (614)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (414)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2106)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (90)
  5. Editorial (83)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1992)
  2. Solid Tumor Oncology Division (1623)
  3. GSK Faculty (765)
  4. Survivorship Research (637)
  5. Population Sciences Research Program (614)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (101)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (484)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4648)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/ paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial
    Meeting Abstract

    Eskander, R. N.; Sill, M.; Miller, A.; Beffa, L.; Moore, R.; Hope, J.; Musa, F.; Mannel, R.; Shahin, M. S.; Canturia, G.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa)
    Meeting Abstract

    Liu, J. F.; Brady, M.; Matulonis, U. A.; Miller, A.; Kohn, E. C.; Swisher, E.; Tew, W.; Cloven, N.; Muller, C.; Bender, D.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC)
    Meeting Abstract

    Sridhar, S.; O'Donnell, P. H.; Flaig, T. W.; Rosenberg, J. E.; Hoimes, C. J.; Milowsky, M. I.; Srinivas, S.; George, S.; McKay, R. R.; Petrylak, D. P.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Consensus views on research priorities for cancer survivorship in older adulthood: A Delphi study
    Meeting Abstract

    Drury, A.; O'Brien, A.; O'Connell, L.; Cosgrave, S.; Hannan, M.; Smyth, C.; Fessele, K.; Sheehan, S.; Harkin, M.; Rogers, L.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial
    Meeting Abstract

    Bardia, A.; Jhaveri, K.; Im, S. A.; Pernas Simon, S.; De Laurentiis, M.; Wang, S.; Martinez, N.; Santos Borges, G.; Cescon, D. W.; Hattori, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Novel therapeutic opportunities in metaplastic breast cancer
    Meeting Abstract

    Pareja, F.; Gazzo, A.; Dopeso, H.; Brown, D.; Selenica, P.; Zhu, Y.; Blanco Heredia, J.; Gusain, L.; Pei, X.; Marra, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Atezolizumab (atezo) and tumour microenvironment in early triple-negative breast cancer (eTNBC): Exploratory biomarker analysis from IMpassion031
    Meeting Abstract

    Harbeck, N.; Duan, C.; DuPree, K.; Chang, C. W.; Barrios, C. H.; Zhang, H. A.; Saji, S.; Jung, K. H.; Telli, M. L.; Liste Hermoso, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • CDC7 inhibition constrains lineage plasticity and prevents resistance and neuroendocrine transformation in the lung and prostate
    Meeting Abstract

    Quintanal-Villalonga, Á.; Zaidi, S.; Karthaus, W. R.; Zhan, Y. A.; Shafer, M.; Qiu, J.; de Stanchina, E.; Haffner, M. C.; Sawyers, C. L.; Rudin, C. M.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Chemotherapy priming leads to hypermutability and immune surveillance in colorectal cancer
    Meeting Abstract

    Vitiello, P. P.; Chilà, R.; Battuello, P.; Battaglieri, V.; Amodio, V.; Grasso, G.; Rospo, G.; Lamba, S.; Pisati, F.; Rousseau, B. J. C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Pan-cancer prevalence of MET fusions and clinical response to MET- targeted therapy
    Meeting Abstract

    Vojnic, M.; Odintsov, I.; Liu, Z.; Lu, D.; Harshan, M.; Ameri, A.; Machnicki, S.; Xiao, X.; Lockwood, W.; Ladanyi, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save